Table 2.

The susceptibility rates of A. baumannii in different ward classification from 2007 to 2013 (n = 1352).

Isolates (n)	Wards	Antimicrobial Agents	Antimicrobials Susceptibility (%) by Year							Correlation
			2007	2008	2009	2010	2011	2012	2013	r	p
Blood (154)	All wards (154)	Imipenem/cilastatin	42.86	36.36	50.00	57.89	32.00	33.33	34.38	−0.39	0.387
		Meropenem	42.86	36.36	52.38	57.89	32.00	33.33	30.00	−0.46	0.294
		MDR-AB	57.14	61.54	42.31	42.86	72.00	72.73	63.64	0.44	0.318
	Non-ICU wards (84)	Imipenem/cilastatin	28.57	60.00	50.00	84.62	35.29	50.00	50.00	0.13	0.788
		Meropenem	28.57	60.00	54.55	84.62	35.29	50.00	47.06	0.07	0.884
		MDR-AB	71.43	50.00	42.86	23.08	70.59	60.00	52.94	−0.04	0.940
	ICU wards (70)	Imipenem/cilastatin	57.14	16.67	50.00	0.00	25.00	16.67	14.29	−0.58	0.175
		Meropenem	57.14	16.67	50.00	0.00	25.00	16.67	7.69	−0.63	0.131
		MDR-AB	42.86	71.43	41.67	75.00	75.00	83.33	75.00	0.33	0.465
Sputum and BAL (1198)	All wards (1198)	Imipenem/cilastatin	25.25	20.00	18.40	19.55	19.31	20.43	14.90	−0.74	0.059
		Meropenem	24.49	20.69	18.01	19.55	17.59	19.46	13.56	−0.83 *	0.021
		MDR-AB	49.36	78.23	83.95	81.54	39.59	75.51	84.76	0.07	0.879
	Non-ICU wards (694)	Imipenem/cilastatin	24.53	22.22	23.30	21.62	20.61	19.19	15.18	−0.92 **	0.003
		Meropenem	25.00	23.33	22.33	21.62	18.60	18.18	13.68	−0.97 **	0.000
		MDR-AB	46.07	75.82	80.39	81.69	83.33	76.19	86.36	0.07	0.879
	ICU wards (504)	Imipenem/cilastatin	26.09	16.36	10.00	16.95	16.90	21.84	14.58	−0.25	0.589
		Meropenem	23.91	16.36	10.34	16.95	15.71	20.93	13.41	−0.29	0.528
		MDR-AB	53.73	82.14	90.00	81.36	84.51	74.73	83.00	−0.25	0.589

* Correlation is significant at the 0.05 level (2-tailed); ** Correlation is significant at the 0.01 level (2-tailed).